TY - JOUR T1 - Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis JF - medRxiv DO - 10.1101/2020.08.13.20174201 SP - 2020.08.13.20174201 AU - Haytham Tlayjeh AU - Olaa H. Mhish AU - Mushira A. Enani AU - Alya Alruwaili AU - Rana Tleyjeh AU - Lukman Thalib AU - Leslie Hassett AU - Yaseen M. Arabi AU - Tarek Kashour AU - Imad M. Tleyjeh Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/14/2020.08.13.20174201.abstract N2 - Background To systematically review the literature about the effect of systemic corticosteroid therapy (CST) on outcomes of COVID-19 patients.Methods We searched Medline, Embase, EBM Reviews, Scopus, Web of Science, and preprints up to July 20, 2020. We included observational studies and randomized controlled trials (RCT) that assessed COVID-19 patients treated with CST. We pooled adjusted effect estimates of mortality and other outcomes using a random effect model, among studies at low or moderate risk for bias. We assessed the certainty of evidence for each outcome using the GRADE approach.Results Out of 1067 citations screened for eligibility, one RCT and 19 cohort studies were included (16,977 hospitalized patients). Ten studies (1 RCT and 9 cohorts) with 10,278 patients examined the effect of CST on short term mortality. The pooled adjusted RR was 0.92 (95% CI 0.69-1.22, I2=81.94 %). This effect was observed across all stages of disease severity. Four cohort studies examined the effect of CST on composite outcome of death, ICU admission and mechanical ventilation need. The pooled adjusted RR was 0.41(0.23-0.73, I2=78.69%). Six cohort studies examined the effect of CST on delayed viral clearance. The pooled adjusted RR was 1.47(95% CI 1.11-1.93, I2=43.38%).Conclusion Heterogeneous and low certainty cumulative evidence suggests that CST lacks efficacy in reducing short-term mortality while possibly delaying viral clearance in patients hospitalized with COVID-19. Because of the discordant results between the single RCT and observational studies, more research should continue to identify the clinical and biochemical characteristics of patients’ population that could benefit from CST.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and materials generated during the current study are available from the corresponding author on reasonable request ER -